Photo: Michael M. Santiago / Getty Images News / Getty Images
The U.S. Food and Drug Administration (FDA) has approved a modified risk claim for Zyn nicotine pouches, allowing them to be marketed with the statement that using Zyn instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. Zyn pouches, which contain nicotine but no tobacco, have been available in the U.S. since January 2025.
The decision marks the first time nicotine pouches have been authorized for sale with a modified risk claim. The FDA's decision has sparked a debate, with some experts expressing concern that consumers might misinterpret the claim as an endorsement of Zyn for smoking cessation. Stanton Glantz and colleagues from the University of California, San Francisco, argue that the claim could be misunderstood as FDA approval for cessation, potentially leading to increased use among young people.
On the other hand, the R Street Institute supports the FDA's decision, stating that the modified risk claim provides smokers with accurate information, encouraging a switch to less harmful alternatives. They emphasize that Zyn pouches deliver nicotine without the harmful byproducts of combustion, such as tar and carbon monoxide.
The FDA's decision aligns with its goal to provide consumers with information that can help them make informed choices about tobacco use. However, the debate highlights the ongoing challenges in balancing public health goals with consumer perceptions.